Accessibility Menu

Abbott Laboratories(FRA) ABL

Market Cap€165.18BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2008)+306%
5 Year-12%
1 Year-16%
1 Month+4%
€96.68
+1.28%
+1.22Today
Abbott Laboratories last closing stock price
MetricPriceDate
Last closeEUR 94.642026-08-31
Abbott Laboratories stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-5.17%EUR 99.802026-08-24
1 month+3.68%EUR 91.282026-07-31
3 month+27.41%EUR 74.282026-06-02
Year to date-10.65%EUR 105.922025-12-30
1 year-15.97%EUR 112.622025-08-29
3 year-0.77%EUR 95.372023-09-01
5 year-11.59%EUR 107.052021-09-01
Since inception+305.58%EUR 23.542008-07-28

Abbott Laboratories Financials at a Glance

Market Cap

€165.18BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

€39.95K

Net Income (TTM)

€4.63K

EPS (TTM)

€2.65

P/E Ratio

35.99

Dividend

€2.13

Beta (Volatility)

0.04 (Low)

Price

€96.68

Volume

0

Open

€96.68

Previous Close

€96.68

Daily Range

€96.68 - €96.68

52-Week Range

€69.76 - €116.80

Estimated Earnings Date

N/A

ABL News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Abbott Laboratories

Abbott Laboratories engages in the discovery, development, manufacture, and sale of a broad and diversified line of health care products. It operates through the following business segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment refers to the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment markets diagnostic systems and tests for blood banks, hospitals, commercial laboratories, and alternate-care testing sites. The Nutritional Products segment caters to the worldwide sales of adult and pediatric nutritional products. The Medical Devices segment includes electrophysiology, heart failure, vascular and structural heart devices for the treatment of cardiovascular diseases, and diabetes care products for people with diabetes, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded by Wallace Calvin Abbott in 1888 and is headquartered in Abbott Park, IL.

Industry

Healthcare Equipment and Supplies

Employees

115,000

CEO

Robert B. Ford, MBA

ABL Financials

Key Financial Metrics (TTM)

Gross Margin

N/A

Operating Margin

N/A

Net Income Margin

N/A

Return on Equity

10.56%

Return on Capital

N/A

Return on Assets

N/A

Earnings Yield

2.78%

Dividend Yield

2.24%

Payout Ratio

N/A

Stock Overview

Market Cap

€165.18BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

1.73B

Volume

0

Avg. Volume

217.152

Financials (TTM)

Gross Profit

N/A

Operating Income

N/A

EBITDA

N/A

Operating Cash Flow

N/A

Capital Expenditure

N/A

Free Cash Flow

N/A

Cash & ST Invst.

N/A

Total Debt

N/A

Abbott Laboratories Performance Analysis

Abbott Laboratories annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31EUR 41,535,743,84314.0%
20232023-12-31EUR 37,099,640,306-10.7%
20242024-12-31EUR 38,781,878,9754.5%
20252025-12-31EUR 39,277,747,6971.3%
Abbott Laboratories annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31EUR 3.7211.8%
20232023-12-31EUR 3.02-19.0%
20242024-12-31EUR 7.06134.2%
20252025-12-31EUR 3.29-53.3%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

€10.83K

+1.1%

Gross Profit

€5.70K

+1.1%

Gross Margin

52.64%

+1.0%

Market Cap

€165.18BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

€1.21

N/A

Employees

115,000

N/A

Net Income

€798.14

+0.5%

EBITDA

€2.38K

+0.9%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

€32.99K

+89.9%

Total Debt

€28.52K

+2.5%

Accounts Receivable

€7.52K

+1.1%

Inventory

€6.40K

+1.1%

Long Term Debt

€25.89K

+2.4%

Short Term Debt

€2.63K

+6.1%

Return on Assets

5.55%

+0.3%

Return on Invested Capital

13.71%

+1.0%

Free Cash Flow

€1.72K

+1.3%

Operating Cash Flow

€2.15K

+1.3%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
^GSPCS&P 500
$7,684.24-0.00%
^DJIDJI
$53,254.61-0.01%
^IXICNASDAQ
$26,319.55-0.00%
BTCBitcoin
$78,890.00-0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
PCGPG&E
$13.27-0.20%
NVDANvidia
$220.78+0.01%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.97+0.11%
CNHCNH Industrial
$11.83+0.01%

Questions About ABL

What is the current price of Abbott Laboratories?

Abbott Laboratories is trading at €96.68 per share.

What is the 52-week range for Abbott Laboratories?

Over the past 52 weeks, Abbott Laboratories has traded between €69.76 and €116.80.

How much debt does Abbott Laboratories have?

As of the most recent reporting period, Abbott Laboratories reported total debt of €28.52B.

How much cash does Abbott Laboratories have on hand?

Abbott Laboratories reported €4.46B in cash and cash equivalents in its most recent financial results.

What is Abbott Laboratories’s dividend yield?

Abbott Laboratories currently has a dividend yield of 2.24%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.